Chromosomal alterations, prognostic factors, and targeted molecular therapies for malignant meningiomas
- PMID: 22743042
- DOI: 10.1016/j.jocn.2012.02.007
Chromosomal alterations, prognostic factors, and targeted molecular therapies for malignant meningiomas
Abstract
Meningiomas are the second most common intracranial neoplasm in adults and originate from arachnoidal cap cells. Malignant meningiomas are resistant to conventional treatments such as surgery, chemotherapy, and radiotherapy. Unlike benign meningiomas, atypical and anaplastic tumors generally display more complex karyotypes associated with aggressive behavior. While these chromosomal anomalies are associated with greater malignancy in meningiomas, the specific genes involved remain unknown. Malignant meningiomas are characterized by increased tumor aggressiveness, rapid recurrence, local invasion, atypical histological appearance, and a high mitotic index. Potential prognostic factors include extent of resection, treatment with radiotherapy or stereotactic radiosurgery, Ki-67/MIB-1 labeling index, p53 overexpression, percentage of tumor cells in the S-phase, telomerase activity, and numerous genetic expression profiles. A greater understanding of prognostic factors and molecular markers involved in critical signaling pathways may aid in the identification of novel therapeutic targets. As such, further studies are needed to establish reliable prognostic factors and develop more effective treatments for malignant meningiomas.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.Neurosurg Focus. 2011 May;30(5):E6. doi: 10.3171/2011.2.FOCUS1116. Neurosurg Focus. 2011. PMID: 21529177 Review.
-
[Meningiomas: new prognostic factors].An R Acad Nac Med (Madr). 2007;124(2):319-32; discussion 330-2. An R Acad Nac Med (Madr). 2007. PMID: 18069599 Spanish.
-
Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas.Neurol India. 2003 Sep;51(3):336-40. Neurol India. 2003. PMID: 14652433
-
Meningioma.Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71. doi: 10.1016/j.critrevonc.2008.01.010. Epub 2008 Mar 14. Crit Rev Oncol Hematol. 2008. PMID: 18342535 Review.
-
Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.APMIS. 2009 Sep;117(9):651-9. doi: 10.1111/j.1600-0463.2009.02516.x. APMIS. 2009. PMID: 19703125
Cited by
-
Prognostic factors for olfactory groove meningioma with nasal cavity extension.Oncotarget. 2017 Dec 19;9(4):4607-4613. doi: 10.18632/oncotarget.23461. eCollection 2018 Jan 12. Oncotarget. 2017. PMID: 29435128 Free PMC article.
-
Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.J Neurooncol. 2019 Dec;145(3):449-459. doi: 10.1007/s11060-019-03333-6. Epub 2019 Nov 15. J Neurooncol. 2019. PMID: 31729637
-
The Evolving Classification of Meningiomas: Integration of Molecular Discoveries to Inform Patient Care.Cancers (Basel). 2024 Apr 30;16(9):1753. doi: 10.3390/cancers16091753. Cancers (Basel). 2024. PMID: 38730704 Free PMC article. Review.
-
Perioperative blood transfusion management in surgical resection of intracranial meningiomas: A meta-analysis.Surg Neurol Int. 2024 Jul 26;15:256. doi: 10.25259/SNI_427_2024. eCollection 2024. Surg Neurol Int. 2024. PMID: 39108382 Free PMC article. Review.
-
Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype.Neuro Oncol. 2014 May;16(5):735-47. doi: 10.1093/neuonc/not325. Epub 2014 Feb 16. Neuro Oncol. 2014. PMID: 24536048 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
